Effector cell combination for preventing and treating tumors and preparation method thereof

Abstract

The invention relates to an effector cell combination for preventing and treating tumors. The effector cell combination comprises CIK (cytokine induced killer) cells and MSC (Mesenchymal Stem Cells) which are sequentially injected into a human body in the form of a cell suspension and are extracted and prepared from peripheral blood of exogenous healthy people in non-tumor patients. The invention also discloses a preparation method of the effector cell combination, and the method comprises the following steps of: blood mononuclear cell collection, CIK cell culture and MSC culture. According to the scheme disclosed by the invention, the CIK cells and the MSC are extracted and prepared from the peripheral blood of the exogenous healthy people in the non-tumor patients, thereby breaking the routine treatment of auto-CIK cells, improving the clinical effects of tumor biotherapy and especially the clinical effects of CIK cell therapy, and solving the problems in graft-versus-host reaction (GVHD).

Description

technical field [0001] The invention relates to the field of medical and biological technologies, in particular to an effector cell combination for preventing and treating tumors and a preparation method thereof. Background technique [0002] Malignant tumors are common and frequently-occurring diseases that seriously endanger human health. The incidence of malignant tumors in the world has increased rapidly year by year. In 2005, the Ministry of Health announced that the number of deaths from cancer has leapt to the top of the top ten causes of death among urban and rural residents in China. The treatment has a long way to go. The US government regards "declaring war on cancer" as one of the basic national policies, investing 2.5 billion US dollars in 15 years. However, the results of tumor prevention and treatment were not satisfactory. After 20 years, the Presidential Committee of the United States concluded the result of "declaring war on cancer": the 5-year survival ra...

AI Technical Summary

Problems solved by technology

The reason is that these patients are older (60% of clinical tumor patients are over 60 years old), and their own cells have poor reproductive ability

In addition, after a long period of chemical drugs and radiation therapy, the blood cells and immune ability of the patient are further damaged, and 40% of patients in clinical practice cannot cultivate autologous CIK cells.

[0008] ② Even if autologous CIK cells can be barely cultured, the expansion multiple and killing activity of the CIK cells are obviously insufficient

[0009] ③This is also the most important and core shortcoming

[0016] In summary, the core of the disadvantages of the above-mentioned technical background is that the clinical curative effect is relatively poor